Brugia malayi

Last updated

Brugia malayi
Brugia malayi.JPG
B. malayi, blood smear, Giemsa stain
Scientific classification OOjs UI icon edit-ltr.svg
Domain: Eukaryota
Kingdom: Animalia
Phylum: Nematoda
Class: Chromadorea
Order: Rhabditida
Family: Onchocercidae
Genus: Brugia
Species:
B. malayi
Binomial name
Brugia malayi
S.L. Brug, 1927

Brugia malayi is a filarial (arthropod-borne) nematode (roundworm), one of the three causative agents of lymphatic filariasis in humans. Lymphatic filariasis, also known as elephantiasis, is a condition characterized by swelling of the lower limbs. The two other filarial causes of lymphatic filariasis are Wuchereria bancrofti and Brugia timori , which both differ from B. malayi morphologically, symptomatically, and in geographical extent. [1]

Contents

B. malayi is transmitted by Mansonia mosquitoes and is restricted to South and Southeast Asia. It is one of the tropical diseases targeted for elimination by the year 2020 by the World Health Organization, which has spurred vaccine and drug development, as well as new methods of vector control.

Signs and symptoms

Brugia malayi
Brugia malayi LifeCycle.gif
The life cycle of Brugia malayi.
Specialty Infectious disease

B. malayi is one of the causative agents of lymphatic filariasis, a condition marked by infection and swelling of the lymphatic system. The disease is primarily caused by the presence of worms in the lymphatic vessels and the resulting inflammatory response of the host. Signs of infection are typically consistent with those seen in Bancroftian filariasis—fever, lymphadenitis, lymphangitis, lymphedema, and secondary bacterial infection—with a few exceptions.[ citation needed ]

Lymphadenitis

Lymphadenitis, the swelling of the lymph nodes, is a commonly recognized symptom of many diseases. It is an early manifestation of filariasis, usually occurs in the inguinal area during B. malayi infection and can occur before the worms mature. [2]

Lymphangitis

Lymphangitis is the inflammation of the lymphatic vessels in response to infection. It occurs early in the course of infection in response to worm development, molting, death, or bacterial and fungal infection. The affected lymphatic vessels become distended and tender, and the overlying skin becomes erythematous and hot. Abscess formation and ulceration of the affected lymph node occasionally occurs during B. malayi infection, more often than in Bancroftian filariasis. Remnants of adult worms can sometimes be found in the ulcer drainage. [2]

Lymphedema

The most obvious sign of infection, elephantiasis, is the enlargement of the limbs–usually the legs. A late complication of infection, elephantiasis is a form of lymphedema and is caused by repeated inflammation of the lymphatic vessels. Repeated inflammatory reactions causes vessel dilation and thickening of the affected lymphatic vessels, which can compromise function. The lymphatic system normally functions to maintain fluid balance between tissues and the blood and serves as an integral part of the immune system. Blockage of these vessels due to inflammatory induced fibrosis, dead worms, or granulomatous reactions can interfere with normal fluid balance, thus leading to swelling in the extremities. [3] Elephantiasis resulting from B. malayi infection typically affects the distal portions of the extremities. Unlike Bancroftian filariasis, B. malayi rarely affects genitalia and does not cause funiculitis, orchitis, epididymitis, hydrocele, or chyluria, conditions more often observed with Bancroftian infection. [2]

Secondary bacterial infection

Secondary bacterial infection is common among patients with filariasis. Compromised immune function due to lymphatic damage in addition to lymph node ulcerations and abscesses exposure and impaired circulation due to elephantiasis can cause secondary bacterial or fungal infection. Elephantiasis, in addition to the physical burden of a swollen limb, can be a severely debilitating condition given bacterial infection. Part of the WHO's "Strategy to Eliminate Lymphatic Filariasis" targets hygiene promotion programs in order to alleviate the suffering of affected individuals (see Prevention Strategies). [2] [4]

However, clinical manifestations of infection are variable and depend on several factors, including host immune system, infectious dose, and parasite strain differences. Most infections appear asymptomatic, yet vary from individual to individual. Individuals living in endemic areas with microfilaremia may never present with overt symptoms, whereas in other cases, only a few worms can exacerbate a severe inflammatory response. [2]

The development of the disease in humans, however, is not well understood. Adults typically develop worse symptoms, given the long exposure time required for infection. Infection may occur during childhood, but the disease appears to take many years to manifest. The incubation period for infection ranges from 1 month to 2 years and typically microfilariae appear before overt symptoms. Lymphedema can develop within six months and development of elephantiasis has been reported within a year of infection among refugees, who are more immunologically naive. Men tend to develop worse symptoms than women. [4]

Hosts

Hosts of B. malayi include Southeast Asian cats. [5]

Cause

Life cycle

Development and replication of B. malayi occurs in two discrete phases: in the mosquito vector and in the human. Both stages are essential to the life cycle of the parasite.[ citation needed ]

Mosquito: The mosquito serves as a biological vector and intermediate host – it is required for the developmental cycle and transmission of B. malayi.
4. The mosquito takes a human blood meal and ingests microfilariae (worm-like sheathed eggs) that circulate in the human blood stream.[ citation needed ]
5-7 In the mosquito, the microfilariae shed sheaths, penetrate the midgut, and migrate to the thoracic muscles were the microfilariae increase in size, molt, and develop into infective larvae (L1 and L3) over a span of 7–21 days. No multiplication or sexual reproduction of microfilariae occurs in the mosquito.[ citation needed ]
8-1 The infective larvae (L3) migrate to the salivary glands, enter the proboscis and escape onto human skin when the mosquito takes another blood meal. [6]

Human: B. malayi undergoes further development in the human as well as sexual reproduction and egg production.
1-2 The infective larvae (L3) actively penetrate the skin through the bite hole and develop into adults in the lymphatic system over a span of 6 months. Adult worms can survive in the lymphatic system for 5–15 years [7]
3. The male and female adult worms mate and the females produce an average of 10,000 sheathed eggs (microfilaria) daily [7] The microfilariae enter the blood stream and exhibit nocturnal periodicity and subperiodicity.[ citation needed ]
4. Another mosquito takes a blood meal and ingests the microfilariae. Infection depends on the mosquito taking a blood meal during a periodic episode – when microfilariae are present in the bloodstream. [6]

Morphology

Adult

Adult worms resemble typical nematode roundworms. Long and threadlike, B. malayi and other nematode possess only longitudinal muscles and move in an S-shape motion. [8] Adults are typically smaller than adult W. bancrofti, though few adults have been isolated. Female adult worms (50 mm) are larger than male worms (25 mm). [9]

Microfilariae

B. malayi microfilariae are 200–275  µm in length and have a round anterior end and a pointed posterior end. The microfilariae are sheathed, which stains heavily with Giemsa. The sheath is actually the egg shell, a thin layer that surrounds the egg shell as the microfilariae circulates in the bloodstream. The microfilariae retain the sheath until they are digested in the mosquito midgut. [2]

B. malayi microfilariae resemble W. bancrofti and Loa loa microfilariae with minor differences that can aid in laboratory diagnosis. B. malayi microfilariae can be distinguished by the noncontinuous row of nuclei found in the tip of the tail. There are two terminal nuclei that are distinctly separated from the other nuclei in the tail, whereas the tail of W. bancrofti contains no nuclei and Loa loa microfilariae nuclei form a continuous row in the tail. B. malayi microfilariae also have a characteristic cephalic space ratio of 2:1. [10]

Spread

B. malayi is transmitted by a mosquito vector. The principal mosquito vectors include Mansonia, Anopheles , and Aedes mosquitoes. [11] [2] The geographical distribution of the disease is thus dependent on suitable mosquito breeding habitat.[ citation needed ]

The accumulation of many infective mosquito bites – several hundreds to thousands – is required to establish infection. This is because a competent mosquito usually transmits only a few infective L3 larvae (see Life cycle), and less than 10% of those larvae progress through all the necessary molting steps and develop into adult worms that can mate. [13] Thus those at greatest risk for infection are individuals living in endemic areas—short term tourists are unlikely to develop lymphatic filariasis. [14]

Diagnosis

Tender or enlarged inguinal lymph nodes or swelling in the extremities can alert physicians or public health officials to infection.[ citation needed ]

With appropriate laboratory equipment, microscopic examination of differential morphological features of microfilariae in stained blood films can aid diagnosis—in particular the examination of the tail portion, the presence of a sheath, and the size of the cephalic space. [2] Giemsa staining will uniquely stain B. malayi sheath pink. [10] However, finding the microfilariae on blood films can be difficult because of the nocturnal periodicity of some forms of B. malayi.[ citation needed ]

PCR based assays are highly sensitive and can be used to monitor infections both in humans and the mosquito vectors. However, PCR assays are time-consuming, labor-intensive and require laboratory equipment. Lymphatic filariasis mainly affects the poor, who live in areas without such resources. [15]

The ICT antigen card test is widely used in the diagnosis of W. bancrofti, but commercial antigens of B. malayi have not been widely available. However, new research developments have identified a recombinant antigen (BmR1) that is both specific and sensitive in the detection of IgG4 antibodies against B. malayi and B. timori in an enzyme-linked immunosorbent assay and an immunochromatographic rapid dipstick (Brugia Rapid) test. However, it appears that immunoreactivity to this antigen is variable in individuals infected with other filarial nematodes. [16] This research has led to the development of two new rapid immunochromatographic IgG4 cassette tests – WB rapid and PanLF rapid – which detect Bancroftian filariasis and all three species of lymphatic filariasis, respectively, with high sensitivity and selectivity. [15]

Prevention

Vaccines

There is currently no licensed vaccine to prevent lymphatic filariasis. However, recent research has produced vaccine candidates with good results in experimental animals. A glutathione-S-transferase, a detoxification enzyme in parasites isolated from Setaria cervi , a bovine filarial parasite, reduced B. malayi adult parasite burden by more than 82% for 90 days after treatment. [17]

Vector control

Vector control has been effective in virtually eliminating lymphatic filariasis in some regions, but vector control combined with chemotherapy produces the best results. It is suggested that 11 to 12 years of effective vector control may eliminate lymphatic filariasis. [18] Successful methods of B. malayi vector control include residual house spraying using DDT and insecticide treated bednets. Mansonia larvae attach their breathing tubes to underwater roots and plants in order to survive. While chemical larvicides have only provided partial control, plant removal could prevent vector development, but also potential adverse effects on the aquatic environment. Lymphatic filariasis vector control is neglected in comparison to the far more established efforts to control malaria and dengue vectors. Integrated vector control methods should be applied in areas where the same mosquito species is responsible for transmitting multiple pathogens. [19]

Management

The Global Alliance to Eliminate Lymphatic Filariasis was launched by the World Health Organization in 2000 with two primary goals: 1) to interrupt transmission and 2) to alleviate the suffering of affected individuals. Mass drug treatment programs are the main strategy for interrupting parasite transmission, and morbidity management, focusing on hygiene, improves the quality of life of infected individuals. [20]

Drugs

A goal of community-based efforts is to eliminate microfilariae from the blood of infected individuals in order to prevent transmission to the mosquito. This is primarily accomplished through the use of drugs. The treatment for B. malayi infection is the same as for Bancroftian filariasis. Diethylcarbamazine has been used in mass treatment programs as an effective microfilaricidal drug in several locations, including India. [21] While diethylcarbamazine tends to cause adverse reactions like immediate fever and weakness, it is not known to cause any long-term adverse drug effects. It has been shown to kill both adult worms and microfilariae. In Malaysia, diethylcarbamazine dosages (6 mg/kg weekly for 6 weeks; 6 mg/kg daily for 9 days) reduced microfilariae by 80% for 18–24 months after treatment in the absence of mosquito control. [2] Microfilariae numbers slowly return many months after treatment, thus requiring multiple drug doses over time in order to achieve long-term control. However, it is not known how many years of mass drug administration is required to eliminate transmission. there have been any confirmed cases of diethylcarbamazine resistance as of 2007. [21]

Single doses of two drugs (albendazole-diethylcarbamazine and albendazole-ivermectin) have been shown to remove 99% of microfilariae for a year after treatment and help to improve elephantiasis during early stages of the disease. [20] Ivermectin, while not lethal to adult Brugia malayi worms, functions as an effective, less toxic microfilaricide. It disrupts the function of the excretory-secretory apparatus in microfilariae, essential for their survival and immune evasion. [2] [22]

Since the discovery of the importance of Wolbachia bacteria in the life cycle of B. malayi and other nematodes, novel drug efforts have targeted the endobacterium. Tetracyclines, rifampicin, and chloramphenicol have been effective in vitro by interfering with larvae molting and microfilariae development. Tetracyclines have been shown to cause reproductive and embryogenesis abnormalities in the adult worms, resulting in worm sterility. Clinical trials have demonstrated the successful reduction of Wolbachia and microfilariae in onchocerciasis and W. bancrofti infected patients. These antibiotics, while acting through a slightly more indirect route, are promising antifilarial drugs. [23]

Hygiene

Secondary bacterial infection is often observed with lymphatic filariasis. Rigorous hygiene practices, including washing with soap and water daily and disinfecting wounds can help heal infected surfaces, and slow and potentially reverse existing tissue damage. Promoting hygiene is essential for lymphatic filariasis patients given the compromised immune and damaged lymphatic systems and can help prevent suffering and disability. [14] [20]

Preventative chemotherapy

The World Health Organization (WHO) recommends preventive chemotherapy as a key strategy to eliminate lymphatic filariasis. [24] This involves mass drug administration (MDA), where entire at-risk populations are treated annually with safe medicine combinations. The medicines used in MDA are primarily effective against the microfilariae, the immature larvae of the parasite, and have limited effects on the adult worms. [25]

Epidemiology

B. malayi infects 13 million people in south and southeast Asia and is responsible for nearly 10% of the world's total cases of lymphatic filariasis. [18] [19] B. malayi infection is endemic or potentially endemic in 16 countries, where it is most common in southern China and India, but it also occurs in Indonesia, Thailand, Vietnam, Malaysia, the Philippines, and South Korea. [11] The distribution of B. malayi overlaps with W. bancrofti in these regions, but does not coexist with B. timori. [2] Regional foci of endemicity are determined in part by the mosquito vectors [ citation needed ]

History

Distinct parasite

B. malayi was discovered in 1927 by the Dutch parasitologist Steffen Lambert Brug (1879–1946) (who is commonly known in the scientific literature as S.L. Brug) while working in Indonesia. It was similar to another filarial roundworm Wuchereria bancrofti (then called Filaria (Microfilaria) bancrofti). But the new species of human filaria in North Sumatra was both physiologically and morphologically distinct from the W. bancrofti microfilariae commonly found in Jakarta. Based on their resemblance and differences, the new species was named Filaria malayi. [26] Despite epidemiological studies identifying Filaria malayi in India, Sri Lanka, China, North Vietnam, and Malaysia in the 1930s, Lichtenstein and Brug's hypothesis was not accepted until the 1940s, when Rao and Mapelstone identified two adult worms in India. [27]

Based on the similarities with W. bancrofti, Rao and Mapelstone proposed to call the parasite Wuchereria malayi. [26] After the discovery of new species such as W. pahangi (now B. pahangi ) in 1956, and W. patei (now B. patei) in 1958, the scientific classification was reassessed in 1960. Buckley proposed to divide the old genus Wuchereria, into two genera, Wuchereria and introduced a new Brugia after the original discoverer. Then Wuchereria contains only W. bancrofti, which so far has been found to infect only humans, and the genus Brugia contains B. malayi, which infects humans and animals, as well as other zoonotic species. [12]

Different strains

In 1957, two subspecies of human infecting B. malayi were discovered by Turner and Edeson in Malaysia based on the observation of different patterns of microfilaria periodicity. [26] Periodicity refers to a pronounced peak in microfilariae count during a 24‑hour interval when microfilariae are present and detectable in the circulating blood. [12] The basis for this phenomenon remains largely unknown. [2]

Research

In 2007, scientists sequenced the genome of Brugia malayi. [28] Identifying the genes of this organism might lead to development of new drugs and vaccines. [29]

To decipher the genome, "Whole Genome Shotgun Sequencing" was performed. The genome was found to be approximately 90-95 megabases in size. The results of the sequencing were then compared to those of the reference nematode Caenorhabditis elegans , along with its prototype Caenorhabditis briggsae . These two free-living nematodes were incorporated in the study and were important for several reasons:[ citation needed ]

New medications

Sequence comparisons between the two genomes allow for mapping of C. elegans orthologs to B. malayi genes. By using orthology mappings (between C. elegans and B.malayi) and incorporating the extensive genomic and functional genomic data, including genome-wide RNAi screens that already exist for C. elegans, potentially essential genes in B. malayi can be identified. Scientists are hoping to be able to target these genes as potential new targets for drug treatments. The longevity of this parasite complicates treatment because most existing drugs target the larvae and thus do not kill adult worms. The drugs often must be taken periodically for years, and the worms can cause a massive immune reaction when they die and releases foreign molecules in the body. Drug treatments for filariasis have not changed significantly in over 20 years, and with the risk of resistance rising, there is an urgent need for the development of new anti-filarial drug therapies. From the genome sequence, several metabolic pathways have been identified, containing dozens of gene products that may be helpful in the discovery of more targeted and effective drug therapies.[ citation needed ]

These potential new targets for drugs or vaccines may provide new opportunities for understanding, treating and preventing elephantiasis.[ citation needed ]

Relationship with Wolbachia

The relationship between the Wolbachia bacteria and B. malayi is not fully understood. Extrapolating from research done with Wuchereria bancrofti , another nematode that causes filariasis, Wolbachia may aid in embryogenesis of the worm, be responsible for potent inflammatory responses from macrophages and filarial disease, and be linked to the onset of lymphedema and blindness sometimes associated with B. malayi infections. In a study done by the University of Bonn in Ghana, doxycycline effectively depleted Wolbachia from W. bancrofti. It is likely that the mechanism of doxycycline is similar to that in other filarial species, i.e., a predominant blockade of embryogenesis, leading to a decline of microfilariae according to their half-life. This could render doxycycline treatment an additional tool for the treatment of microfilaria-associated diseases in Bancroftian filariasis, along with B. malayi fiariasis. The course of treatment with doxycycline could be much shorter as it would make the adult worm sterile in one shot rather than repeatedly have to target the replenished larvae that current treatments kill, and there would be fewer side effects for the infected individual.[ citation needed ]

Transplant research

Another hopeful use for the research is in the area of transplant research. Because the B. malayi genome is the first parasitic genome to have been sequenced, the implications on the mechanism of parasitism in humans are crucial to understand. According to Alan L. Scott, Ph.D., a collaborator at Johns Hopkins University, understanding how a particular parasite, such as B. malayi, can adapt to humans, may yield medical benefits far beyond treating elephantiasis. According to the author, "This worm can reside in the host for years and not necessarily cause disease, in fact the less disease the individual has, the more worms there are in circulation. Now that we know those genes don't exist in humans we can target them to control disease."[ citation needed ] Some of the predicted proteins for these new genes appear similar to known immuno-modulator proteins, regulators of the immune system, suggesting that they are involved in deactivating the host's immune system to ensure the parasite remains undetected. Knowledge of these previously unknown immune suppressors could also be of use in organ transplants and to help treat autoimmune disease.[ citation needed ]

According to the Filarial Genome Project being done by The Special Programme for Research and Training in Tropical Diseases, the Brugia malayi MIF gene is expressed in all life-cycle stages of the parasite, and results suggest that B. malayi MIF may interact with the human immune system during the course of infection by altering the function of macrophages in the infected individual. Studies are currently testing the hypothesis that MIF may be involved in reducing the host's immune response to the microfilariae. Understanding how this particular parasite has adapted to humans may help organ transplant researchers by figuring out how to prevent the immune system from attacking the transplanted tissue.[ citation needed ]

See also

Related Research Articles

<i>Loa loa</i> filariasis Medical condition

Loa loa filariasis is a skin and eye disease caused by the nematode worm Loa loa. Humans contract this disease through the bite of a deer fly or mango fly, the vectors for Loa loa. The adult Loa loa filarial worm migrates throughout the subcutaneous tissues of humans, occasionally crossing into subconjunctival tissues of the eye where it can be easily observed. Loa loa does not normally affect one's vision but can be painful when moving about the eyeball or across the bridge of the nose. The disease can cause red itchy swellings below the skin called "Calabar swellings". The disease is treated with the drug diethylcarbamazine (DEC), and when appropriate, surgical methods may be employed to remove adult worms from the conjunctiva. Loiasis belongs to the so-called neglected diseases.

<span class="mw-page-title-main">Diethylcarbamazine</span> Chemical compound

Diethylcarbamazine is a medication used in the treatment of filariasis including lymphatic filariasis, tropical pulmonary eosinophilia, and loiasis. It may also be used for prevention of loiasis in those at high risk. While it has been used for onchocerciasis, ivermectin is preferred. It is taken by mouth.

<span class="mw-page-title-main">Filariasis</span> Parasitic disease caused by a family of nematode worms

Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These are spread by blood-feeding insects such as black flies and mosquitoes. They belong to the group of diseases called helminthiases.

<i>Wuchereria bancrofti</i> Species of parasitic worm

Wuchereria bancrofti is a filarial (arthropod-borne) nematode (roundworm) that is the major cause of lymphatic filariasis. It is one of the three parasitic worms, together with Brugia malayi and B. timori, that infect the lymphatic system to cause lymphatic filariasis. These filarial worms are spread by a variety of mosquito vector species. W. bancrofti is the most prevalent of the three and affects over 120 million people, primarily in Central Africa and the Nile delta, South and Central America, the tropical regions of Asia including southern China, and the Pacific islands. If left untreated, the infection can develop into lymphatic filariasis. In rare conditions, it also causes tropical pulmonary eosinophilia. No vaccine is commercially available, but high rates of cure have been achieved with various antifilarial regimens, and lymphatic filariasis is the target of the World Health Organization Global Program to Eliminate Lymphatic Filariasis with the aim to eradicate the disease as a public-health problem by 2020. However, this goal was not met by 2020.

<i>Wolbachia</i> Genus of bacteria in the Alphaproteobacteria class

Wolbachia is a genus of intracellular bacteria that infects mainly arthropod species, including a high proportion of insects, and also some nematodes. It is one of the most common parasitic microbes, and is possibly the most common reproductive parasite in the biosphere. Its interactions with its hosts are often complex, and in some cases have evolved to be mutualistic rather than parasitic. Some host species cannot reproduce, or even survive, without Wolbachia colonisation. One study concluded that more than 16% of neotropical insect species carry bacteria of this genus, and as many as 25 to 70% of all insect species are estimated to be potential hosts.

Brugia pahangi is a parasitic roundworm belonging to the genus Brugia. It is a filarial nematode known to infect the lymph vessels of domestic cats and wild animals, causing a disease filariasis.

Acanthocheilonema is a genus within the family Onchocercidae which comprises mainly tropical parasitic worms. Cobbold created the genus Acanthocheilonema with only one species, Acanthocheilonema dracunculoides, which was collected from aardwolf in the region of South Africa in the nineteenth century. These parasites have a wide range of mammalian species as hosts, including members of Carnivora, Macroscelidea, Rodentia, Pholidota, Edentata, and Marsupialia. Many species among several genera of filarioids exhibit a high degree of endemicity in studies done on mammalian species in Japan. However, no concrete evidence has confirmed any endemic species in the genus Acanthocheilonema.

Acanthocheilonemiasis is a rare tropical infectious disease caused by a parasite known as Acanthocheilonema perstans. It can cause skin rashes, abdominal and chest pains, muscle and joint pains, neurological disorders and skin lumps. It is mainly found in Africa. The parasite is transmitted through the bite of small flies. Studies show that there are elevated levels of white blood cells.

<span class="mw-page-title-main">Lymphatic filariasis</span> Medical condition

Lymphatic filariasis is a human disease caused by parasitic worms known as filarial worms. Usually acquired in childhood, it is a leading cause of permanent disability worldwide, impacting over a hundred million people and manifesting itself in a variety of severe clinical pathologies While most cases have no symptoms, some people develop a syndrome called elephantiasis, which is marked by severe swelling in the arms, legs, breasts, or genitals. The skin may become thicker as well, and the condition may become painful. Affected people are often unable to work and are often shunned or rejected by others because of their disfigurement and disability.

In population ecology, density-dependent processes occur when population growth rates are regulated by the density of a population. This article will focus on density dependence in the context of macroparasite life cycles.

<i>Mansonella perstans</i> Species of roundworm

Mansonella perstans is a filarial (arthropod-borne) nematode (roundworm), transmitted by tiny blood-sucking flies called midges. Mansonella perstans is one of two filarial nematodes that causes serous cavity filariasis in humans. The other filarial nematode is Mansonella ozzardi. M. perstans is widespread in many parts of sub-Saharan Africa, parts of Central and South America, and the Caribbean.

Mansonelliasis is the condition of infection by the nematode Mansonella. The disease exists in Africa and tropical Americas, spread by biting midges or blackflies. It is usually asymptomatic.

Brugia timori is a filarial (arthropod-borne) nematode (roundworm) which causes the disease "Timor filariasis", or "Timorian filariasis". While this disease was first described in 1965, the identity of Brugia timori as the causative agent was not known until 1977. In that same year, Anopheles barbirostris was shown to be its primary vector. There is no known animal reservoir host.

<span class="mw-page-title-main">Onchocercidae</span> Family of roundworms

The Onchocercidae are a family of nematodes in the superfamily Filarioidea. This family includes some of the most devastating human parasitic diseases, such as lymphatic filariasis, onchocerciasis, loiasis, and other filariases.

<span class="mw-page-title-main">Filarioidea</span> Superfamily of roundworms

The Filarioidea are a superfamily of highly specialised parasitic nematodes. Species within this superfamily are known as filarial worms or filariae. Infections with parasitic filarial worms cause disease conditions generically known as filariasis. Drugs against these worms are known as filaricides.

<i>Culex quinquefasciatus</i> Species of fly

Culex quinquefasciatus, commonly known as the southern house mosquito, is a medium-sized mosquito found in tropical and subtropical regions of the world. It is a vector of Wuchereria bancrofti, avian malaria, and arboviruses including St. Louis encephalitis virus, Western equine encephalitis virus, Zika virus and West Nile virus. It is taxonomically regarded as a member of the Culex pipiens species complex. Its genome was sequenced in 2010, and was shown to have 18,883 protein-coding genes.

Tropical pulmonary eosinophilia, is characterized by cough, bronchospasm, wheezing, abdominal pain, and an enlarged spleen. Occurring most frequently in the Indian subcontinent and Southeast Asia, TPE is a clinical manifestation of lymphatic filariasis, a parasitic infection caused by filarial roundworms that inhabit the lymphatic vessels, lymph nodes, spleen, and bloodstream. Three species of filarial roundworms, all from the Onchocercidae family, cause human lymphatic filariasis: Wuchereria bancrofti, Brugia malayi, and Brugia timori.

<span class="mw-page-title-main">Elodie Ghedin</span> Parasitologist and a virologist

Elodie Ghedin is a Canadian parasitologist and virologist as well as a professor at the New York University Center for Genomics and Systems Biology. Her work focuses on the molecular biology and genomics of the parasites that cause diseases such as elephantiasis, and river blindness, and on the evolution of the influenza virus. She was named a 2011 MacArthur Fellow, a 2012 Kavli Frontier of Science Fellow, and a 2017 American Academy of Microbiology Fellow. She also was Awarded the Chancellor’s Distinguished Research Award in 2010.

<i>Brugia</i> Genus of roundworms

Brugia is a genus for a group of small roundworms. They are among roundworms that cause the parasitic disease filariasis. Specifically, of the three species known, Brugia malayi and Brugia timori cause lymphatic filariasis in humans; and Brugia pahangi and Brugia patei infect domestic cats, dogs and other animals. They are transmitted by the bite of mosquitos.

Lymphatic filariasis in India refers to the presence of the disease lymphatic filariasis in India and the social response to the disease. In India, 99% of infections come from a type of mosquito spreading a type of worm through a mosquito bite. The treatment plan provides 400 million people in India with medication to eliminate the parasite. About 50 million people in India were carrying the worm as of the early 2010s, which is 40% of all the cases in the world. In collaboration with other countries around the world, India is participating in a global effort to eradicate lymphatic filariasis. If the worm is eliminated from India then the disease could be permanently eradicated. In October 2019 the Union health minister Harsh Vardhan said that India's current plan is on schedule to eradicate filariasis by 2021.

References

  1. Johhn, David T., and William A. Petri. Markell and Voge's Medical Parasitology. 9th ed. St. Louis: Saunders Elsevier, 2006.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 John, David T. & Petri, William A. (2006), Markell and Voge's Medical Parasitology (9th ed.), St. Louis: Saunders Elsevier, ISBN   978-0-7216-4793-7 .
  3. Cross, John H. (1996), "Filarial Nematodes: Lymphatic Filariae Wuchereria Bancrofti and Brugia Malayi", Medical Microbiology (4th ed.), The University of Texas Medical Branch at Galveston. The National Institutes of Health, ISBN   9780963117212 .
  4. 1 2 "Lymphatic filariasis", The World Health Organization, World Health Organization .
  5. "Brugia malayi". American Association of Veterinary Parasitologists . 2010-01-01. Archived from the original on 2022-01-16. Retrieved 2022-01-16.
  6. 1 2 "Life cycle of Brugia Malayi". The Centers for Disease Control. 2018-09-19. Archived from the original on 2013-01-21. Retrieved 2009-03-05.
  7. 1 2 Southwick, Frederick S. (2007), Infectious Disease: A Clinical Short Course (2nd ed.), New York: McGraw Hill Professional, ISBN   978-0-07-147722-2 .
  8. Decraemer, W.; Karanastasi, E.; Brown, D. & Backeljau, T. (2003), "Review of the ultrastructure of the nematode body cuticle and its phylogenetic interpretation", Biological Reviews, 78 (3): 465–510, doi:10.1017/S1464793102006115, PMID   14558593, S2CID   9146013 .
  9. "Brugia malayi". Web Atlas of Medical Parasitology.
  10. 1 2 "Bench aids for the diagnosis of filarial infections. Plate 2 – Brugia malayi, Brugia timori". World Health Organization. 1997. Archived from the original on 2013-02-15. Retrieved 2009-03-05.
  11. 1 2 3 "Gideon Infectious Diseases Online. Brugia Malayi".
  12. 1 2 3 4 5 Edeson, J. F. B. & Wilson, T. (1964), "The epidemiology of filariasis due to Wuchereria Bancrofti and Brugia Malayi", Annual Review of Entomology, 9: 245–268, doi:10.1146/annurev.en.09.010164.001333 .
  13. Fischer, P.; Erickson, S. M.; Fischer, K.; Fuchs, J. F.; Rao, R. U.; Christensen, B. M. & Weil, G. J. (2007), "Persistence of Brugia Malayi DNA in vector and non-vector mosquitoes: implication for xenomonitoring and transmission monitoring of lymphatic filariasis", American Journal of Tropical Medicine and Hygiene, 76 (3): 502–507, doi:10.4269/ajtmh.2007.76.502, PMC   2196403 , PMID   17360875
  14. 1 2 "Lymphatic Filariasis: Epidemiology and Risk Factors". The Centers for Disease Control and Prevention. 2018-08-30.
  15. 1 2 Noordin, R.; Itoh, M.; Kimura, E.; Rahman, R.; Ravindran, B.; Mahmud, R.; Supali, T. & Weerasooriya, M. (2007), "Multicentre evaluations of two new rapid IgG4 tests (WB rapid and PanLF rapid) for detection of lymphatic filariasis", Filaria Journal, 6 (9): 9, doi: 10.1186/1475-2883-6-9 , PMC   2174453 , PMID   17961262 .
  16. Noordin, R.; Aziz, R. & Ravindran, B. (2004), "Homologs of the Brugia malayi diagnostic antigen BmR1 are present in other filarial parasites but induce different humoral immune responses", Filaria Journal, 3 (10): 10, doi: 10.1186/1475-2883-3-10 , PMC   544840 , PMID   15627400 .
  17. Rathaur, S.; Yadav, M.; Gupta, S.; Anandharaman, V. & Reddy, Maryada Venkatarami (2008), "Filarial glutathione-S-transferase: a potential vaccine candidate against lymphatic filariasis", Vaccine, 26 (32): 4094–4100, doi:10.1016/j.vaccine.2008.03.099, PMID   18499308 .
  18. 1 2 Remme J.H.F., Feenstra P., Lever P.R., Medici A., Morel C., Noma M., Ramaiah K.D., Richards F., Seketeli A., Schmunis G., van Brakel W.H., and Anna Vassall. Chapter 22. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis, and leprosy. Book: Disease Control Priorities in Developing Countries.
  19. 1 2 Chang, M. S. (2002), "Operational issues in the control of the vectors of Brugia", Annals of Tropical Medicine and Parasitology, 96 (2): S71–S76, doi:10.1179/000349802125002392, PMID   12625920 .
  20. 1 2 3 "Lymphatic filariasis". The World Health Organization.
  21. 1 2 Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane Database of Systematic Reviews, 2007.
  22. Moreno, Yovany; Nabhan, Joseph F.; Solomon, Jonathan; Mackenzie, Charles D.; Geary, Timothy G. (2010-11-16). "Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi". Proceedings of the National Academy of Sciences of the United States of America. 107 (46): 20120–20125. doi:10.1073/pnas.1011983107. ISSN   1091-6490. PMC   2993382 . PMID   21041637.
  23. Rao, R. U. (2005), "Endosymbiotic Wolbachia of parasitic filarial nematodes as drug targets" (PDF), The Indian Journal of Medical Research, 122 (3): 199–204, PMID   16251775, archived from the original (PDF) on 2010-12-15, retrieved 2010-03-23.
  24. "Lymphatic filariasis". www.who.int. Retrieved 2023-12-14.
  25. "Global programme to eliminate lymphatic filariasis: progress report, 2020". www.who.int. Retrieved 2023-12-14.
  26. 1 2 3 Sasa, Manabu (1979). "A review on classification and geographic distribution on brugian filariasis" (PDF). Joint WPRO/SEARO Working Group on Brugian Filariasis. World Health Organizatioin. Archived from the original (PDF) on 2011-06-04. Retrieved 2009-03-05.
  27. Shiyung, Liu (2006). "Filaria and plasmodium: distribution of endemic diseases and western plain exploitation in Taiwan" (PDF). XIV International Economic History Congress, Helsinki 2006, Session 46.
  28. Ghedin, E.; Wang, S.; Spiro, D.; et al. (September 21, 2007). "Draft Genome of the Filarial Nematode Parasite Brugia malayi". Science. 317 (5845): 1756–1760. Bibcode:2007Sci...317.1756G. doi:10.1126/science.1145406. ISSN   0036-8075. PMC   2613796 . PMID   17885136.
  29. Dunham, Will (September 20, 2007). "Genome deciphered for elephantiasis-causing worm". Reuters. Retrieved January 30, 2018.